There’s no link between vaccination to protect against hepatitis B and the risk of developing multiple sclerosis (MS) in childhood, a new study finds.
A number of previous studies have investigated a possible association between the hepatitis B vaccine and MS in adults and most found no evidence of increased short- or long-term risk of MS. However, the studies were criticized for problems with their methodology, including how participants’ vaccination status was confirmed. This controversy created public doubts about the hepatitis B vaccine, according to background information in the study.
In this new study, French researchers compared 143 children who developed MS before age 16 with a control group of 1,122 age- and sex-matched MS-free participants in the general population.
About 32 percent of both the MS patients and the control group participants had received the hepatitis B vaccine.
Vaccination against hepatitis B within the three-year study period was not associated with an increased rate of a first episode of MS. “The rate was also not increased for hepatitis B vaccination within six months of the index date or any time since birth or as a function of the number of injections or the brand of hepatitis B vaccine,” the study authors wrote.
“Vaccination against hepatitis B does not seem to increase the risk of a first episode of MS in childhood,” they concluded.